Price movement over the last 24 hours
AdaptHealth Corp vs Zscaler Inc — how do they compare? AdaptHealth Corp trades at $10.07 (market cap $1.38B), while Zscaler Inc trades at $144.33 (market cap $24.18B). The key difference: Zscaler Inc is far larger — about 17.5× AdaptHealth Corp's market cap, and AdaptHealth Corp is trading nearer its 52-week high, Zscaler Inc nearer its low. Which is the better fit depends on your goals.
| AHCO | ZS | |
|---|---|---|
Market Cap | $1.38B | $24.18B |
Sector | Health | Technology |
52-Week High | $13.38 | $336.27 |
52-Week Low | $8.68 | $118.05 |
Enterprise Value | $3.33B | $22.50B |
Signals from Pluang's Aura AI — not financial advice
AdaptHealth (AHCO) trades at $10.27, down 4.55% today, with neutral technical signals and mixed fundamental performance. The company reported Q1 2026 earnings miss with negative EPS of -$0.06 versus $0.0125 expected, continuing a pattern of recent quarterly misses. Despite revenue growth to $3.3B projected for 2026, net income remains negative with -2.43% margin. Analyst consensus remains bullish with 75% buy ratings and $14.80 price target, representing 44% upside potential from current levels.
The investment case balances strong analyst support and reasonable valuation (P/S 0.42, EV/EBITDA 7.17) against persistent profitability challenges. Recent refinancing improves financial flexibility, but execution on cost controls and margin improvement remains critical. The stock offers significant upside if management can translate revenue growth into sustainable profitability, though current negative earnings trend presents near-term headwinds.
Zscaler (ZS) trades at $149.50, up 1.47% with strong technical momentum and bullish moving average signals. The company shows impressive revenue growth from $1.1B in 2022 to $2.67B in 2025, though remains unprofitable with a -2.44% net margin. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $1.08 surpassing the $1.01 forecast. Technical indicators show the stock trading near pivot point resistance at $149 with support at $145.
ZS presents a growth investment case with 79% analyst buy ratings and $192.64 consensus target, offering 29% upside. However, profitability challenges, ongoing class action investigations, and projected negative 2026 cash flow pose significant risks. The stock's high valuation multiples (P/S 7.53, EV/EBITDA 157.24) require sustained growth execution to justify current levels.
Trailing returns across standard periods
AdaptHealth provides patient-centered healthcare-at-home solutions in the U.S. It offers medical equipment and supplies for sleep therapy, respiratory health, diabetes management, and general home wellness.
Read more on AHCO →Zscaler is a security-as-a-service firm that offers its customers cloud-delivered solutions for protecting user devices and data. The firm leverages its position in 150 colocation data centers to deliver traditionally appliance-based security functionality, such as firewalls and sandboxes, as a completely cloud-native platform. The firm focuses on large enterprise customers and offers two primary product suites: Zscaler Internet Access, which securely connects users to externally managed application and websites (such as Salesforce and Google), and Zscaler Private Access, which securely connects users to internally managed applications. Both product suites encompass a broad gamut of capabilities situated across the traditional security stack.
Read more on ZS →